[ad_1]
Emergent Biosolutions EBS shares ended the last trading session 12.5% higher at $14.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock’s 0.5% gain over the past four weeks.
Share price rose after management announced that the FDA advisory committee unanimously recommended approval of the company’s supplemental new drug application (sNDA) seeking to make opioid overdose reversal drug Narcan (naxolone) nasal spray available without a prescription throughout the U.S. The FDA generally follows the recommendation of its advisory committee. Investors likely cheered as they expect a positive FDA decision on the sNDA.
This biopharmaceutical company is expected to post quarterly earnings of $0.32 per share in its upcoming report, which represents a year-over-year change of -92.9%. Revenues are expected to be $307.73 million, down 57.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Emergent Biosolutions, the consensus EPS estimate for the quarter has been revised 1.1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn’t usually translate into price appreciation. So, make sure to keep an eye on EBS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Emergent Biosolutions is part of the Zacks Medical – Biomedical and Genetics industry. Rapt Therapeutics RAPT, another stock in the same industry, closed the last trading session 2.7% higher at $28.64. RAPT has returned 4.3% in the past month.
For Rapt Therapeutics
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
Rapt Therapeutics (RAPT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Image and article originally from www.nasdaq.com. Read the original article here.